Given the pathogenic role of dysregulated cGAS-STING signaling in autoimmune disorders, targeting TRIM21’s E3 ubiquitin ligase activity could open new avenues for developing precision therapeutics to modulate this pathway in SLE and related conditions. This evidence concerns the gene CGAS and systemic lupus erythematosus.